Peptides, FDA's Pharmacy Compounding Advisory Committee, and the Future of FDA Drug Approval.

The FDA Pharmacy Compounding Advisory Committee recommended adding 7 peptides to the compounding 503A Bulks List, raising concerns about threats to drug approval and patients.

• Why it matters: The work addresses a potential gap in how peptide compounding could undermine the FDA drug-approval process and patient protections.
• What they did: It reviews the committee’s recommendation and frames the implications of adding 7 peptides to the compounding 503A Bulks List.
• The result: The viewpoint argues that compounding these peptides could pose a profound threat to drug approval and patients, implying heightened regulatory risk.